FSD Stock Recent News

-Jobless claims at an eight-week low -Tesla plans full self driving launch in China and Europe -Nippon Steel's US Steel bid faces Biden barrier Manus Cranny reports. Tune into "Bloomberg Brief" at 5 a.m.

Toronto, Ontario--(Newsfile Corp. - August 9, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the proposed consolidation of its issued and outstanding class A multiple voting shares ("Class A Multiple Voting Shares") and class B subordinate voting shares ("Class B Subordinate Voting Shares") of the Company on the basis of one (1) post-consolidation Class A Multiple Voting Share and Class B Subordinate Voting Share for every sixty-five (65) pre-consolidation Class A Multiple Voting Shares and Class B Subordinate Voting Shares (the "Consolidation"). This ratio is within the ratio range approved by the Company's stockholders at its annual general and special meeting held on July 22, 2024.

FSD Pharma (NASDAQ: HUGE ) stock is taking off on Friday after the biopharmaceutical company provided investors with an update on its investment in Celly Nutrition . FSD Pharma notes that Celly Nutrition is closing in on the launch of its “unbuzzd” product.

TORONTO, ON / ACCESSWIRE / August 9, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update on its investment in Celly Nutrition Corp. ("Celly Nu"), a privately held Canadian company launching an innovative beverage product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption. On August 9, 2024, Celly Nutrition which is backed by a world-class pharmaceutical research & development team at FSD Pharma, operated by CEO John Duffy, formerly of Coca-Cola, and co-chaired by Gerry David the former CEO of Celsius Holdings (CELH) proudly announces the imminent launch of its revolutionary, great tasting and scientifically backed product, unbuzzd™.

Denver, Colorado--(Newsfile Corp. - July 25, 2024) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, today publishes a news report highlighting functional beverage market developments, featuring FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9). FSD Pharma (NASDAQ: HUGE) To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10481/217645_fsdpharmalogo.jpg To read the full article on 247marketnews.com, please click here.

Denver, Colorado--(Newsfile Corp. - July 23, 2024) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, today publishes a news report highlighting small cap market biotech developments, featuring FSD Pharma (NASDAQ: HUGE). FSD Pharma (NASDAQ: HUGE) To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10481/217432_2c52394c544c9bc9_logo_lg.jpg To read the full article on 247marketnews.com, please click here The report discusses FSD Pharma's revolutionary rapid alcohol detoxification drink, UNBUZZD™, which helps to rapidly restore mental alertness post-alcohol consumption.

This article discusses the upcoming merger of First Trust High Income Long/Short Fund into abrdn Income Credit Strategies Fund. The merger of FSD into ACP was approved, with shares to de-list on July 19, 2024. FSD shareholders to receive NAV for NAV shares in ACP, which is trading at a premium to NAV.

PHILADELPHIA, PA / ACCESSWIRE / July 9, 2024 / The Board of Trustees of abrdn Income Credit Strategies Fund (NYSE:ACP) ("ACP" or the "Acquiring Fund") previously announced that shareholders of First Trust High Income Long/Short Fund (NYSE:FSD) ("FSD" or the "Acquired Fund"), advised by First Trust Advisors L.P., have approved the proposed reorganization into ACP ("Reorganization") and today announces that the Reorganization is expected to close at the close of business on July 19, 2024, subject to the satisfaction of customary closing conditions.

Toronto, Ontario--(Newsfile Corp. - July 4, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced today that it has filed an amended and restated its material change report dated December 7, 2023 (the "Original MCR"), in order to amend the disclosure in Section 5.1 of the Original MCR. The amended and restated material change report (the "Amended and Restated MCR") is being filed to provide additional disclosure with respect of the private placement offering of Class A Multiple Voting Shares of the Company (the "MVS") that closed on December 5, 2023 (the "Offering").

WHEATON, Ill.--(BUSINESS WIRE)--First Trust Advisors L.P. (“FTA”) previously announced that shareholders of First Trust High Income Long/Short Fund (NYSE: FSD) (“FSD”), a diversified, closed-end management investment company organized as a Massachusetts business trust, have approved the reorganization of FSD with and into abrdn Income Credit Strategies Fund (“ACP”), a diversified, closed-end management investment company organized as a Delaware statutory trust. Subject to the satisfaction of ce.